Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00363727 | Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's | PHASE3 | COMPLETED | 209 | — | — | Dec 1, 2003 | Jan 1, 2006 | Jan 18, 2017 | 69 | United States |
Median time to dyskinesia could not be estimated by Kaplan-Meier methods because of the small number of events; however, number of participants with dyskinesia requiring days from the date of randomization (Day 1) to the date at which a participant has the event of interest were reported
| Name | Type | Description |
|---|---|---|
| ropinirole controlled-release (REQUIP CR) for RLS | DRUG | - |
Inclusion Criteria: * Must be on 600mg or less of levodopa therapy for two years or less. * Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening. Exclusion Criteria: * Current or past history of Dyskinesia. * State of dementia or have a MMSE score \< 26 at screenin...